Skip to main content
main-content

Video commentaries


Expert commentaries from clinicians and researchers on clinical trials, guidelines and topical issues in diabetes care.


EASD 2020 interviews

09-30-2020 | EASD 2020 | Conference coverage | Article

DAPA-CKD: Does confirmed renoprotection make the case for first-line SGLT2 inhibition?

Luigi Gnudi reflects on what the findings of DAPA-CKD mean for diabetologists, nephrologists, and treatment guidelines (6:10).

09-29-2020 | EASD 2020 | Conference coverage | Article

EMPEROR-Reduced: Time for a change in the HF guidelines?

Miles Fisher comments on the findings from the EMPEROR-Reduced trial, which demonstrated cardioprotective effects of empagliflozin irrespective of diabetes in patients with heart failure, and discusses whether SGLT2 inhibitors should be incorporated into heart failure treatment guidelines (5:08).

09-25-2020 | EASD 2020 | Conference coverage | Article

DAPA-CKD trial: Renal benefits of SGLT2 inhibition in people with and without diabetes

DAPA-CKD lead investigator Hiddo Heerspink discusses the positive outcomes of dapagliflozin treatment in people with kidney disease both with and without type 2 diabetes (8:13).

09-25-2020 | EASD 2020 | Conference coverage | Article

EMPEROR-Reduced: Empagliflozin benefits in HF patients irrespective of diabetes

Lead investigator Milton Packer compares the EMPEROR-Reduced results with those of the DAPA-HF trial, and talks about how SGLT2 inhibitors will impact the treatment of heart failure (6:27).

09-24-2020 | EASD 2020 | Conference coverage | Article

The LIBERATES trial: Flash glucose monitoring post-ACS in people with type 2 diabetes

Ramzi Ajjan discusses lessons learned from flash glucose monitoring in people with type 2 diabetes in the weeks following an acute coronary syndrome in the LIBERATES trial (11:40) .

09-24-2020 | EASD 2020 | Conference coverage | Article

COVID-19 and diabetes: The current evidence

Juliana Chan outlines current knowledge about the relationship between diabetes and COVID-19, discussing risk factors for poor outcomes in people with both conditions and the need for collaborative efforts to improve patient care (7:09).

ADA 2020 interviews

06-18-2020 | ADA 2020 | Conference coverage | Video

Expert commentary: The VERTIS-CV trial

Francesco Giorgino comments on the findings from the VERTIS-CV trial, and discusses the cardiovascular efficacy and safety of ertugliflozin in the context of the SGLT2 inhibitor class (10:10).

06-16-2020 | ADA 2020 | Conference coverage | Video

Researcher comment: The VERTIS-CV trial

Lead investigator Chris Cannon discusses the VERTIS-CV trial, showing that the SGLT2 inhibitor ertugliflozin is noninferior to placebo for the prevention of major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (7:16).

06-15-2020 | ADA 2020 | Conference coverage | Video

Researcher comment: Putting telehealth into practice for type 2 diabetes

Matthew Crowley discusses the successful implementation of a telehealth service for rural people with type 2 diabetes in clinical practice and its relevance to the current pandemic (13:07).

06-14-2020 | ADA 2020 | Conference coverage | Video

Expert commentary: Icosapent ethyl lowers cardiovascular risk in people with diabetes

Jay Shubrook comments on a subgroup analysis of the REDUCE-IT trial demonstrating that icosapent ethyl reduces the risk for cardiovascular events in statin-treated patients with diabetes (3:39).

View more videos commentaries

Featuring expert interviews from our 2019 conference coverage.


Image Credits